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HMP – Human Microbiome Project 
MTB – Mycobacterium tuberculosis 
BP – Bordetella pertussis  
CR – cockroaches  
SFC - spot forming cell 
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Abstract 
Several mechanisms exist to avoid or suppress inflammatory T cell immune 
responses that could prove harmful to the host due to targeting self-antigens or 
commensal microbes. We hypothesized that these mechanisms could become 
evident when comparing the immunogenicity of a peptide from a pathogen or 
allergen with the conservation of its sequence in the human proteome or the healthy 
human microbiome. Indeed, performing such comparisons on large sets of validated 
T cell epitopes, we found that epitopes that are similar with self-antigens above a 
certain threshold showed lower immunogenicity, presumably as a result of negative 
selection of T cells capable of recognizing such peptides. Moreover, we also found a 
reduced level of immune recognition for epitopes conserved in the commensal 
microbiome, presumably as a result of peripheral tolerance. These findings indicate 
that the existence (and potentially the polarization) of T cell responses to a given 
epitope is influenced and to some extend predictable based on its similarity to self-
antigens and commensal-antigens. 
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Introduction 
Several methods are available that can accurately predict binding of peptides to 
MHCI and MHCII molecules (1–5). Binding to an MHC molecule is an essential 
though not sufficient criterion for a peptide to be recognized by T cells as an immune 
target. Other factors play a role, such as the ability of a MHCI binding peptide to be 
processed from its source protein (6–11), and the amino acid composition of the 
peptide, which has been linked to immunogenicity presumably by some residues 
being more visible to the T cell receptor (12, 13). However, there are significant 
factors influencing T cell immunogenicity beyond the factors mentioned above that 
remain unknown. This is particularly evident for MHC class II restricted epitopes, 
where binding predictions correlate well with measured binding affinities (5), but 
when attempting to predict immunogenic peptides the performance is far from 
perfect (14). We have recently demonstrated that a combination of HLA class II 
binding predictions selecting a set of top 20% candidate peptides will cover 50% of 
the immune response (15).  While this is practically very useful, it also demonstrates 
that mechanisms beyond MHC binding affinity shape immune recognition patterns 
(14).  
One effect that is expected to influence immunogenicity of a given peptide is the 
suppression of immune responses that could be harmful to the host. T cells reacting 
to peptides conserved in the human proteome are expected to be deleted by 
negative selection during T cell maturation. In addition, it has been postulated that 
inflammatory T cells reactive to peptides found in commensal microorganisms will be 
suppressed by regulatory T cells - a mechanism called peripheral tolerance. 
However, the extent to which these mechanisms imprint on the T cell immune 
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repertoire and thereby impact the immune recognition of peptides from pathogens or 
allergens has not been systematically analyzed or quantified.  
In this study, we examined if there is evidence for tolerization in immune recognition 
patterns by correlating immune responses of peptides from bacterial pathogens and 
allergens with the sequence conservation of these peptides in the human proteome 
and in proteins identified in the Human Microbiome Project (HMP). We find that there 
is evidence for both.  
 
Methods 
Peptide immunogenicity dataset assembly 
Peptides from three independent studies were utilized. The first dataset consisted of 
15-mer peptides from Mycobacterium tuberculosis (MTB) antigens tested for 
recognition in IFNg ELISPOT assays using peripheral blood mononuclear cells 
(PBMC) from individuals latently infected with MTB (16, 17). The second dataset 
consisted of 16-mer peptides overlapping antigens included in the B. pertussis 
vaccine, tested for recognition in IFNg ELISPOT assays by PBMCs from previously 
vaccinated individuals (manuscript in preparation). The third dataset consisted of 15-
mer peptides contained in antigens encoded in cockroach proteins and tested for 
recognition in IL-5 ELISPOTs by PBMCs from allergic individuals (18, 19). All assays 
were performed in triplicates and included media stimulated cells as a background 
control. Individual experiment were considered positive if the number of spot forming 
cells (SFC) above background was more than 20 per million input cells and the 
number of IFNg producing cells after peptide stimulation was significantly above 
background based on a Student’s t-test p-value < 0.05 and a stimulation index > 2.0. 
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This combination of positivity criteria is commonly used in our laboratory, including in 
the studies cited above. To classify a peptide overall as positive in the donor cohort, 
the SFC from individual experiments that met the positivity criteria were added up, 
and the total SFC as well as the number of positive experiments were utilized as 
positivity cutoffs as specified in the results section.  
 
Human proteome and microbiome sequence dataset assembly 
Protein sequences from the human proteome were downloaded from UniProt 
(www.uniprot.org) (20) using the query: keyword:"Complete proteome" AND 
organism:"Homo sapiens (Human) [9606]". The sequences were downloaded using 
the “Download” option, choosing “Download all” and Format: FASTA (canonical & 
isoform). Protein sequences from the human gut microbiome were retrieved from the 
Human Microbiome Project (HMP) (21, 22). The data was downloaded from the 
HMP Data Analysis and Coordination Center (www.hmpdacc.org/HMRGD), where 
annotated reference genomes could be found. The complete set of annotated 
reference genomes was downloaded as protein sequences in fasta format, by 
choosing “Download all” in protein multifasta (PEP) format for with the body site 
specified as ‘gastrointestinal tract’. 
 
Quantifying peptide similarity to protein sequences 
For a given peptide of length N, we define the similarity score of that peptide with 
sequence a as the highest score for an equal length amino acid stretch b in the set 
of target proteins, where the match score is given by the formula 
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in which bl(a,b) is the sum of the BLOSUM62 matrix (23) values for substituting 
residues in peptide a for the residues in amino acid stretch b.  
 
Results 
Assembly of a peptide immunogenicity dataset  
Immunogenicity can be assessed by different assays, and differs substantially 
between antigenic systems due to variances in the route of exposure to the antigens. 
We thus only compared immunogenicity of peptides from the same antigenic source 
and tested in the same assay systems. We utilized datasets from three studies 
representing different modes of exposure: infection with Mycobacterium tuberculosis 
(MTB), vaccination with Bordetella pertussis (BP) and inhalation of allergens from 
cockroaches (CR). In each of these datasets, a large numbers of peptides (>500) 
had been tested in a consistent fashion by ELISPOT assays in a large (>30) number 
of donors. For the cockroach dataset, peptides were considered positive if they had 
significant responses in at least two donors (t-test p-value < 0.05, SI >2, SFC>20), 
and if the total number of spot forming cells per million (SFC) summed over all 
donors in the cohort was greater than one hundred. For the M. tuberculosis and B. 
pertussis datasets, reactivities were higher in general, and the cutoff for positivity 
was set to 3 reacting donors and a total SFC>200. Peptides were considered 
negative if they did not give a significant response in any single donor. Peptides with 
intermediate reactivities were discarded. These selection criteria take into account 
inherent differences in assays and immunization procedures to ensure that the 
positive set capture 70% or more of the total reactivity. Table 1 lists the number of 
positive and negative peptides as well as the number of donors for each of the 
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datasets. Supplementary Table 1 lists the peptide sequences and their 
immunogenicity classification. 
 
Quantifying peptide similarity 
In order to compare the bacterial and allergen derived peptides tested for 
immunogenicity with the human proteome and human microbiome, we needed to 
define a quantitative score of similarity. A simple approach is to count the number of 
different amino acids in two sequences, but this neglects that some exchanges of 
amino acids alter the properties of a peptide significantly more than others. To 
account for this, we quantified amino acid similarity using a BLOSUM similarity score 
described in the methods section, which quantifies amino acid similarity based on 
large scale protein alignments. This score will give peptides with an identical match a 
similarity score of 1.0, regardless of the amino acid composition and length of the 
peptides. The bigger differences between two sequences are according to the 
BLOSUM matrix, the lower the score. Figure 1 illustrates the ranges of similarity 
scores for peptides with varying numbers of amino acids exchanges. While a single 
amino acid exchange results in scores in the range from 0.901 to 0.987,  (90% 
confidence interval displayed in Figure 1), for multiple exchanges the score range is 
much broader (from 0.536 to 0.771). The score ranges for a given number of 
substitutions are provided here as a reference of how the BLOSUM scores should be 
interpreted. 
Correlating peptide immunogenicity with similarity to the human proteome 
To identify if negative selection of self-reactive T cells reduces the immunogenicity of 
peptides that are similar to the human proteome, we calculated the peptide similarity 
of immunogenic peptides (epitopes) and negative peptides from our three datasets 
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to the human proteome. Figure 2 shows the cumulative distribution of similarity 
scores for three datasets. For all three datasets, epitopes had a slightly but 
significantly lower median similarity to self-peptides than non-epitopes, as shown in 
Table 1 (pertussis: 0.485 vs. 0.493, p = 0.049; tuberculosis: 0.507 vs. 0.515, p = 
0.037; cockroach: 0.513 vs. 0.534, p = 0.008). This confirms that immunogenic MHC 
class II restricted peptides have a tendency to be less similar to self-peptides.  
 
Correlating peptide immunogenicity with similarity to the human gut 
microbiome 
Next, we assessed in an analog fashion if there was a detectable reduction in 
immune reactivity for peptides that had similar matches in the human gut 
microbiome. Figure 3 shows the cumulative distribution of similarity scores for 
epitopes and non-epitopes from the three datasets. For both the pertussis and 
cockroach datasets, epitopes had a significantly lower median similarity to the gut 
microbiome compared to non-epitopes as assessed by a one-tailed Mann-Whitney 
test (pertussis: 0.558 vs. 0.571, p=0.012; cockroach: 0.580 vs. 0.599, p = 0.0002). 
The MTB dataset showed the same trend, but did not reach the significance of p < 
0.05 in this test (0.584 vs. 0.590; p = 0.11). All median similarity scores can be seen 
in Table 3. Thus MHC class II restricted epitopes also have a tendency to be less 
similar to peptides found in the healthy gut microbiome.   
 
Combining human and microbiome conservation scores 
To determine if the similarity scores of a peptide to the human proteome and the 
human gut microbiome can be combined to better predict immunogenicity, we 
performed a linear regression of the two scores calculating the total score = offset  - 
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βmicrobiome * scoremicrobiome - βhuman * scorehuman , where the three model parameters are 
1) a constant offset, and 2) βmicrobiome and 3) βhuman
 are weights of the gut microbiome 
and the human proteome similarity scores, respectively. The model parameters were 
fitted by calculating the total score of a set of peptides, and minimizing the squared 
difference to their immunogenicity, with immunogenic peptides set to 1.0 and non-
immunogenic peptides set to 0.0. Fitted model parameters determined in 20-fold 
cross-validation are listed in Table 4. The fitted model parameters indicated that the 
microbiome score gets assigned nearly double the weight of the human proteome 
score (0.66 vs. 0.39), suggesting that it has higher predictive power in this model. 
The average cross-validated distance for the combined model is 0.1458. This 
distance is statistically significantly lower when comparing it with a model including 
only the human proteome score (distance = 0.1471; p = 0.025 (one-sided, paired t-
test)), and shows the same trend but does not reach statistical significance when 
compared to a model including only the microbiome score (distance = 0.1459, p = 
0.13). These data suggest that both scores provide independent information on the 
immunogenicity of a peptide, and that the microbiome score has higher predictive 
value in this simple model. 
 
Discussion 
Previous studies for MHC class I restricted epitopes had shown that there is 
evidence for negative selection against peptides that are similar to the human 
proteome (24). In this study, we have expanded those findings for MHC class II 
restricted epitopes, and in addition demonstrated for the first time that there is a 
correlation between a peptide’s T cell immune reactivity and its conservation in the 
microbiome. This suggests that there is an imprint on the availability of T cells 
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recognizing certain peptide targets that shape the development of immune response 
against subsequent exposures.  
Our study provides proof of principle that it should be possible to include similarity to 
self and the microbiome as selection factors into prediction pipelines for MHC class II 
restricted epitopes and adaptive T cell immunotherapy (25). Given the discrepancy 
between our ability to predict MHC class II binding and MHC class II T cell 
immunogenicity (14), any such additional factors are highly desirable. However, at 
the current stage, the magnitude of the detected differences in similarity to either the 
human proteome or the microbiome are very small. As a result, incorporating the 
current similarity scores into epitope prediction pipelines would be expected to only 
give marginal improvements. Additional improvements will be necessary, such as 
better understanding which species in the microbiome have selective impact on the 
epitope repertoire, or by developing better similarity matrices that quantify which 
amino acid substitutions are considered conservative in the context of T cell immune 
recognition. Similarly, the present study was limited to three datasets, representing 
different types of antigen exposure (infection, vaccination and allergen exposure). 
Future studies will explore in much more detail if and how this observation holds in 
different antigenic systems, and how the scores can best be combined with other 
factors to derive overall immunogenicity predictions.  
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Figure Legends 
Figure 1 – The relationship between number of amino acid exchanges and the 
BLOSUM score. Twenty thousand peptides were randomly selected from UniProt 
proteins and compared to the human gut microbiome in terms of BLOSUM score. 
The figure shows the average and 5th percentile – 95th percentile range of the 
generated scores as a function of the number of amino acid substitutions between 
the peptides.   
 
Figure 2 – Similarity of epitopes and non-epitopes to the human proteome. 
Each panel shows the cumulative distribution of similarity scores for epitopes (blue 
line) and non-epitopes (red-line). The different panels depict peptides from A) B. 
pertussis, B) M. tuberculosis and C) cockroach.  
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Figure 3 – Similarity of epitopes and non-epitopes to proteins encoded by 
microbes found in healthy human gut. Each panel shows the cumulative 
distribution of similarity scores for epitopes (blue line) and non-epitopes (red-line). 
The different panels depict peptides from A) B. pertussis, B) MTB and C) cockroach.  
 
 
Tables 
 
Dataset #positive 
peptides 
#negative 
peptides 
#intermediate 
peptides 
#donors 
tested 
M. tuberculosis 79 523 148 61 
B. pertussis 142 300 206 31 
Cockroach 59 437 170 90 
 
Table 1: Peptide immunogenicity datasets 
 
Dataset median similarity score, 
positive peptides (Standard 
deviation) 
median similarity score, 
negative peptides 
(Standard deviation) 
M. tuberculosis 0.507 (0.048) 0.515 (0.048) 
B. pertussis 0.485 (0.041) 0.493 (0.047) 
Cockroach 0.513 (0.094) 0.534 (0.107) 
 
Table 2: Median similarity scores of epitopes and non-epitopes to the human 
proteome. 
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Dataset median similarity score, 
positive peptides (Standard 
deviation) 
median similarity score, 
negative peptides 
(Standard deviation) 
M. tuberculosis 0.584 (0.044) 0.590 (0.059) 
B. pertussis 0.558 (0.052) 0.571 (0.053) 
Cockroach 0.580 (0.046) 0.599 (0.073) 
 
Table 3: Median similarity scores of epitopes and non-epitopes to the human 
gut microbiome. 
 
 
 
Model 
Parameter fit (standard deviation) 
Distance 
offset β microbiome β human 
both parameters 0.78 (0.02) 0.66 (0.04) 0.39 (0.03) 0.1458 
microbiome only 0.69 (0.02) 0.85 (0.04) N/A 0.1459 
human only 0.50 (0.02) N/A 0.6 (0.03) 0.1471 
 
Table 4: Linear regression combining microbiome and human proteome 
scores to predict immunogenicity. 
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